Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics Inc (NQ: APRE )

5.350 -0.260 (-4.63%)
Streaming Delayed Price Updated: 2:53 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,291
Open 5.590
Bid (Size) 5.070 (2)
Ask (Size) 5.980 (5)
Prev. Close 5.610
Today's Range 5.311 - 5.785
52wk Range 2.780 - 8.847
Shares Outstanding 5,430,215
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga

Performance

YTD
+7.00%
+7.00%
1 Month
-17.69%
-17.69%
3 Month
-0.74%
-0.74%
6 Month
+31.15%
+31.15%
1 Year
+36.13%
+36.13%

More News

Read More
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Aprea Therapeutics: Q4 Earnings Insights
Via Benzinga
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
From Aprea Therapeutics
Via GlobeNewswire
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
From Aprea Therapeutics
Via GlobeNewswire
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
From Aprea Therapeutics
Via GlobeNewswire
Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Aprea Therapeutics to Present at BIO International Convention
From Aprea Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.